Switch theme
Sign up to access all valuation multiples
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
2008
834
LTM Revenue $206M
LTM EBITDA -$244M
$324M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ginkgo Bioworks has a last 12-month revenue (LTM) of $206M and a last 12-month EBITDA of -$244M.
In the most recent fiscal year, Ginkgo Bioworks achieved revenue of $227M and an EBITDA of -$484M.
Ginkgo Bioworks expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ginkgo Bioworks valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $206M | XXX | $227M | XXX | XXX | XXX |
| Gross Profit | $162M | XXX | $182M | XXX | XXX | XXX |
| Gross Margin | 78% | XXX | 80% | XXX | XXX | XXX |
| EBITDA | -$244M | XXX | -$484M | XXX | XXX | XXX |
| EBITDA Margin | -118% | XXX | -213% | XXX | XXX | XXX |
| EBIT | -$447M | XXX | -$488M | XXX | XXX | XXX |
| EBIT Margin | -216% | XXX | -215% | XXX | XXX | XXX |
| Net Profit | -$450M | XXX | -$547M | XXX | XXX | XXX |
| Net Margin | -218% | XXX | -241% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Ginkgo Bioworks's stock price is $7.
Ginkgo Bioworks has current market cap of $407M, and EV of $324M.
See Ginkgo Bioworks trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $324M | $407M | XXX | XXX | XXX | XXX | $-8.55 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Ginkgo Bioworks has market cap of $407M and EV of $324M.
Ginkgo Bioworks's trades at 1.4x EV/Revenue multiple, and -0.7x EV/EBITDA.
Equity research analysts estimate Ginkgo Bioworks's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ginkgo Bioworks has a P/E ratio of -0.9x.
See valuation multiples for Ginkgo Bioworks and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $407M | XXX | $407M | XXX | XXX | XXX |
| EV (current) | $324M | XXX | $324M | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | -1.3x | XXX | -0.7x | XXX | XXX | XXX |
| EV/EBIT | -0.7x | XXX | -0.7x | XXX | XXX | XXX |
| EV/Gross Profit | 2.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.9x | XXX | -0.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGinkgo Bioworks's last 12 month revenue growth is -9%
Ginkgo Bioworks's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.8M for the same period.
Ginkgo Bioworks's rule of 40 is -336% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ginkgo Bioworks's rule of X is -142% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Ginkgo Bioworks and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -9% | XXX | -6% | XXX | XXX | XXX |
| EBITDA Margin | -118% | XXX | -213% | XXX | XXX | XXX |
| EBITDA Growth | -39% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -336% | XXX | -223% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -142% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 187% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 295% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| NetraMark | XXX | XXX | XXX | XXX | XXX | XXX |
| SyntekaBio | XXX | XXX | XXX | XXX | XXX | XXX |
| Absci | XXX | XXX | XXX | XXX | XXX | XXX |
| Bullfrog AI | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ginkgo Bioworks acquired XXX companies to date.
Last acquisition by Ginkgo Bioworks was XXXXXXXX, XXXXX XXXXX XXXXXX . Ginkgo Bioworks acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Ginkgo Bioworks founded? | Ginkgo Bioworks was founded in 2008. |
| Where is Ginkgo Bioworks headquartered? | Ginkgo Bioworks is headquartered in United States of America. |
| How many employees does Ginkgo Bioworks have? | As of today, Ginkgo Bioworks has 834 employees. |
| Who is the CEO of Ginkgo Bioworks? | Ginkgo Bioworks's CEO is Dr. Jason Kelly. |
| Is Ginkgo Bioworks publicy listed? | Yes, Ginkgo Bioworks is a public company listed on NYS. |
| What is the stock symbol of Ginkgo Bioworks? | Ginkgo Bioworks trades under DNA ticker. |
| When did Ginkgo Bioworks go public? | Ginkgo Bioworks went public in 2021. |
| Who are competitors of Ginkgo Bioworks? | Similar companies to Ginkgo Bioworks include e.g. Benevolent AI, NetraMark, SyntekaBio, Absci. |
| What is the current market cap of Ginkgo Bioworks? | Ginkgo Bioworks's current market cap is $407M |
| What is the current revenue of Ginkgo Bioworks? | Ginkgo Bioworks's last 12 months revenue is $206M. |
| What is the current revenue growth of Ginkgo Bioworks? | Ginkgo Bioworks revenue growth (NTM/LTM) is -9%. |
| What is the current EV/Revenue multiple of Ginkgo Bioworks? | Current revenue multiple of Ginkgo Bioworks is 1.6x. |
| Is Ginkgo Bioworks profitable? | Yes, Ginkgo Bioworks is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Ginkgo Bioworks? | Ginkgo Bioworks's last 12 months EBITDA is -$244M. |
| What is Ginkgo Bioworks's EBITDA margin? | Ginkgo Bioworks's last 12 months EBITDA margin is -118%. |
| What is the current EV/EBITDA multiple of Ginkgo Bioworks? | Current EBITDA multiple of Ginkgo Bioworks is -1.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
